A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RXRX SEC filings page.
Recursion Pharmaceuticals, Inc. (RXRX) reported $68.2M in revenue over the twelve months to Sep 30, 2026, up 56.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Recursion remains a development-stage business: revenue is growing, but research spending and operating losses are expanding faster than commercial output.
Revenue grew26.9% while cost of revenue grew56.8% in FY2025. Gross margin then fell 18.1 percentage points to5.0% , so added activity did not translate into better unit economics.
R&D consumed
Liabilities fell
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Recursion Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Recursion Pharmaceuticals, Inc. held $743.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $371.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Recursion Pharmaceuticals, Inc. scores 52/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Recursion Pharmaceuticals, Inc. scores 23/100 on it among other emerging companies.
Recursion Pharmaceuticals, Inc. spent $475.3M on research and development in fiscal year 2025, which was 65.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Recursion Pharmaceuticals, Inc. scores 85/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Recursion Pharmaceuticals, Inc. scores 70/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Recursion Pharmaceuticals, Inc. scores 36/100 on it among other emerging companies.
Recursion Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $743.3M at the end of fiscal year 2025, against $343.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Recursion Pharmaceuticals, Inc. scores 76/100 among other emerging companies.
Recursion Pharmaceuticals, Inc. scores 0.13, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $2.1B against total assets of $1.5B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Recursion Pharmaceuticals, Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Recursion Pharmaceuticals, Inc. reported a net loss of $644.8M while operations used $371.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Recursion Pharmaceuticals, Inc. reported an operating loss of $648.1M against $1.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Recursion Pharmaceuticals, Inc. generated $18.6M in revenue in Q3 2026. This represents an increase of 258.5% from the same quarter a year earlier. Against the prior quarter it is up 141.9%.
Recursion Pharmaceuticals, Inc.'s EBITDA was -$106.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Recursion Pharmaceuticals, Inc. reported a net loss of $119.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Recursion Pharmaceuticals, Inc. earned -$0.22 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Recursion Pharmaceuticals, Inc. recorded an outflow of $77.8M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Recursion Pharmaceuticals, Inc. held $549.9M in cash against $93K in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Recursion Pharmaceuticals, Inc.'s gross margin was 45.9% in Q3 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 95.7 percentage points. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Recursion Pharmaceuticals, Inc.'s quarterly ROE was -13.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Recursion Pharmaceuticals, Inc. invested $99.1M in research and development in Q3 2026. This represents a decrease of 18.1% from the same quarter a year earlier. Against the prior quarter it is up 10.6%.
Recursion Pharmaceuticals, Inc. invested $407K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 67.5% from the same quarter a year earlier. Against the prior quarter it is up 825.0%.
Not reported for Q3 2026.
RXRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.6M+258.5% | $7.7M-60.1% | $6.5M-56.1% | $35.5M+681.7% | $5.2M-80.2% | $19.2M+33.3% | $14.7M+6.9% | $4.5M-58.3% |
| Cost of Revenue | $10.0M-31.6% | $11.5M-43.0% | $12.5M-42.8% | $14.3M+11.6% | $14.7M+21.6% | $20.2M+119.2% | $21.8M+95.5% | $12.8M+29.5% |
| Gross Profit | $8.5Mn/m | -$3.8Mn/m | -$6.0Mn/m | $21.3Mn/m | -$9.5M-167.9% | -$938K-118.0% | -$7.1M-369.6% | -$8.2M-915.8% |
| R&D Expenses | $99.1M-18.1% | $89.6M-30.3% | $87.9M-32.2% | $95.9M-2.4% | $121.1M+62.3% | $128.6M+74.0% | $129.6M+91.9% | $98.3M+41.5% |
| SG&A Expenses | $32.6M-21.8% | $41.5M-11.0% | $34.6M-36.7% | $33.7M-56.4% | $41.6M+10.3% | $46.7M+46.6% | $54.6M+74.0% | $77.2M+153.4% |
| Operating Income | -$123.2Mn/m | -$135.0Mn/m | -$128.5Mn/m | -$108.3Mn/m | -$172.2Mn/m | -$176.2Mn/m | -$191.4Mn/m | -$183.8Mn/m |
| EBITDA | -$106.6Mn/m | -$116.8Mn/m | -$108.8Mn/m | -$88.9Mn/m | -$151.2Mn/m | -$152.4Mn/m | -$172.0Mn/m | -$170.8Mn/m |
| Interest Expense | $266K-68.1% | $309K-35.6% | $350K-31.1% | -$11K-101.8% | $833K+50.6% | $480K+21.8% | $508K+2440.0% | $605K+2140.7% |
| Income Tax | $25K+733.3% | -$1Kn/m | -$4.6Mn/m | $19K+137.5% | $3K-98.2% | $0n/m | -$158Kn/m | $8Kn/m |
| Net Income | -$119.0Mn/m | -$131.0Mn/m | -$117.5Mn/m | -$108.1Mn/m | -$162.3Mn/m | -$171.9Mn/m | -$202.5Mn/m | -$178.9Mn/m |
| EPS (Basic) | -$0.22n/m | -$0.25n/m | -$0.22n/m | -$0.17 | -$0.36 | -$0.41 | -$0.50 | -$0.57n/m |
| EPS (Diluted) | -$0.22n/m | -$0.25n/m | -$0.22n/m | -$0.17 | -$0.36 | -$0.41 | -$0.50 | -$0.57n/m |
| Diluted Shares (Avg) | 543M+21.5% | 532M+27.6% | 529M+31.4% | N/A | 447M | 417M | 403M | N/A |
RXRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B-12.7% | $1.2B-6.9% | $1.3B+2.6% | $1.5B+1.8% | $1.4B+92.6% | $1.3B+67.9% | $1.3B+134.0% | $1.4B+121.6% |
| Current Assets | $616.0M-13.7% | $603.5M+2.8% | $709.6M+21.5% | $812.8M+13.8% | $714.1M+50.6% | $587.2M+12.4% | $584.1M+70.0% | $714.3M+63.0% |
| Cash & Equivalents | $549.9M-16.7% | $545.7M+3.9% | $654.5M+30.8% | $743.3M+25.1% | $659.8M+54.3% | $525.1M+10.7% | $500.5M+68.9% | $594.4M+51.8% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $160.7M-0.8% | $160.3M-2.4% | $160.2M+1.3% | $162.2M+8.9% | $162.0M+211.3% | $164.3M+215.6% | $158.1M+203.7% | $148.9M+186.0% |
| Total Liabilities | $315.9M-10.4% | $297.7M-22.3% | $314.8M-15.2% | $343.3M-17.0% | $352.6M+74.6% | $383.2M+100.2% | $371.3M+136.9% | $413.8M+117.5% |
| Current Liabilities | $122.9M-20.8% | $119.9M-26.9% | $129.7M-8.7% | $147.7M-21.2% | $155.1M+42.4% | $164.0M+90.5% | $142.0M+92.1% | $187.5M+101.2% |
| Non-Current Liabilities | $193.0M-2.3% | $177.8M-18.9% | $185.1M-19.3% | $195.6M-13.6% | $197.5M+112.2% | $219.2M+108.1% | $229.3M+177.0% | $226.3M+133.1% |
| Long-Term Debt | $93K-99.2% | $4.8M-66.5% | $7.2M-56.3% | $9.6M-49.7% | $11.9M-42.0% | $14.2M-38.1% | $16.4M+1435.6% | $19.0M+1627.7% |
| Total Equity | $905.8M-13.5% | $915.0M-0.5% | $1.0B+9.7% | $1.1B+9.3% | $1.0B+99.6% | $919.1M+57.3% | $933.9M+132.8% | $1.0B+123.3% |
| Retained Earnings | -$2.4Bn/m | -$2.3Bn/m | -$2.2Bn/m | -$2.1Bn/m | -$2.0Bn/m | -$1.8Bn/m | -$1.6Bn/m | -$1.4Bn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
RXRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$77.4Mn/m | -$105.9Mn/m | -$81.1Mn/m | -$46.1Mn/m | -$117.4Mn/m | -$76.4Mn/m | -$132.0Mn/m | -$115.4Mn/m |
| Depreciation & Amortization | $16.5M-21.4% | $18.2M-23.8% | $19.7M+1.8% | $19.5M+50.4% | $21.0M+192.3% | $23.8M+165.9% | $19.3M+162.0% | $13.0M+71.5% |
| Stock-Based Compensation | N/A | $19.3M-25.2% | $22.2M-38.4% | N/A | $25.0M+41.1% | $25.8M+61.7% | $36.1M+123.6% | N/A |
| Capital Expenditures | $407K+67.5% | $44K-98.6% | $258K-85.9% | $1.2M-4.2% | $243K-94.7% | $3.1M+166.5% | $1.8M-72.5% | $1.3M-37.2% |
| Free Cash Flow | -$77.8Mn/m | -$106.0Mn/m | -$81.4Mn/m | -$47.3Mn/m | -$117.6Mn/m | -$79.6Mn/m | -$133.8Mn/m | -$116.7Mn/m |
| Investing Cash Flow | -$407Kn/m | -$2.0Mn/m | -$338Kn/m | -$1.2M-100.5% | -$2.5Mn/m | -$5.8Mn/m | -$7.3Mn/m | $275.5Mn/m |
| Financing Cash Flow | $83.1M-66.9% | -$1.3M-101.3% | -$3.5M-108.6% | $132.0M+1140.8% | $251.3M+1426.8% | $97.7M-62.9% | $40.5M+191.6% | $10.6M-86.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RXRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | -49.8%-44.9pp | -93.0%-44.9pp | 59.8% | -183.8% | -4.9%-41.1pp | -48.0%-67.1pp | -181.4% |
| Operating Margin | -664.0% | -1759.7% | -1985.6% | -304.8% | -3327.6% | -916.8% | -1297.9% | -4042.4% |
| Net Margin | -641.6% | -1708.0% | -1815.6% | -304.2% | -3135.3% | -894.2% | -1373.3% | -3935.5% |
| Return on Equity | -13.1%+2.4pp | -14.3%+4.4pp | -11.5%+10.2pp | -9.6%+7.7pp | -15.5%+2.8pp | -18.7%-2.0pp | -21.7%+1.1pp | -17.3%+2.8pp |
| Return on Assets | -9.7%+1.9pp | -10.8%+2.4pp | -8.8%+6.7pp | -7.3%+5.0pp | -11.6%+1.6pp | -13.2%-0.6pp | -15.5%+0.9pp | -12.3%+1.9pp |
| Current Ratio | 5.01+0.4x | 5.03+1.5x | 5.47+1.4x | 5.50+1.7x | 4.60+0.2x | 3.58-2.5x | 4.11-0.5x | 3.81-0.9x |
| Debt-to-Equity | 0.000.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.020.0x | 0.020.0x | 0.020.0x |
| Liabilities-to-Equity | 0.350.0x | 0.33-0.1x | 0.31-0.1x | 0.30-0.1x | 0.340.0x | 0.42+0.1x | 0.400.0x | 0.400.0x |
| Asset Turnover | 0.020.0x | 0.010.0x | 0.000.0x | 0.020.0x | 0.000.0x | 0.010.0x | 0.010.0x | 0.000.0x |
| FCF Margin | -419.4% | -1381.9% | -1257.1% | -133.1% | -2272.5% | -413.9% | -907.4% | -2567.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. RXRX | FY2025 | $74.7M | -$644.8M | N/A | $1.7B | 57/100 |
| Fortrea Holdings Inc. FTRE | FY2025 | $2.7B | -$986.2M | -36.2% | $1.9B | 22/100 |
| Maze Therapeutics, Inc. MAZE | FY2025 | N/A | -$131.1M | N/A | $1.8B | — |
| Zymeworks Inc. ZYME | FY2025 | $106.0M | -$81.1M | -76.6% | $1.8B | 79/100 |
| Nurix Therapeutics, Inc. NRIX | FY2025 | $84.0M | -$264.5M | N/A | $1.6B | 55/100 |
| Zenas BioPharma, Inc. ZBIO | FY2025 | $10.0M | -$377.7M | N/A | $1.9B | 37/100 |
Where Recursion Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Recursion Pharmaceuticals, Inc. (RXRX) reported $74.7M in total revenue for fiscal year 2025. This represents a 26.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Recursion Pharmaceuticals, Inc. (RXRX) revenue grew by 26.9% year-over-year, from $58.8M to $74.7M in fiscal year 2025.
No, Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $475.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $644.8M.
Recursion Pharmaceuticals, Inc. (RXRX) had EBITDA of -$564.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Recursion Pharmaceuticals, Inc. (RXRX) had $743.3M in cash and equivalents against $9.6M in long-term debt.
Recursion Pharmaceuticals, Inc. (RXRX) had a gross margin of 5.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Recursion Pharmaceuticals, Inc. (RXRX) has a return on equity of -57.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Recursion Pharmaceuticals, Inc. (RXRX) recorded an outflow of $378.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Recursion Pharmaceuticals, Inc. (RXRX) recorded an outflow of $371.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Recursion Pharmaceuticals, Inc. (RXRX) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
Recursion Pharmaceuticals, Inc. (RXRX) invested $6.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Recursion Pharmaceuticals, Inc. (RXRX) invested $475.3M in research and development during fiscal year 2025.
Recursion Pharmaceuticals, Inc. (RXRX) had a current ratio of 5.50 as of fiscal year 2025, which is generally considered healthy.
Recursion Pharmaceuticals, Inc. (RXRX) had a debt-to-equity ratio of 0.01 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Recursion Pharmaceuticals, Inc. (RXRX) had a liabilities-to-equity ratio of 0.30 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Recursion Pharmaceuticals, Inc. (RXRX) had a return on assets of -43.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Recursion Pharmaceuticals, Inc. (RXRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.7B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Recursion Pharmaceuticals, Inc. (RXRX) trades at 24.8x sales, its market capitalization divided by $68.2M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.7B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Recursion Pharmaceuticals, Inc. (RXRX) held $743.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $371.8M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Recursion Pharmaceuticals, Inc. (RXRX) has an Altman Z-Score of 0.13, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Recursion Pharmaceuticals, Inc. (RXRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $644.8M while operations used $371.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Recursion Pharmaceuticals, Inc. (RXRX) reported an operating loss of $648.1M against $1.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Recursion Pharmaceuticals, Inc. (RXRX) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.